Novartis Acquires Pikavation Therapeutics and PI3K? Inhibitor Portfolio from Synnovation for Up to $3 Billion

Leila Ahmed North America Legal Chronicle
Tagged:

Goodwin Procter and Mintz have advised Synnovation Therapeutics on the transaction. Novartis has entered into a definitive agreement to acquire Pikavation Therapeutics, Inc., a wholly-owned subsidiary…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Leila Ahmed

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here